References
- Seifert SA, Boyer LV, Benson BE, et al. AAPCC database characterization of native U.S. venomous snake exposures, 2001-2005. Clin Toxicol. 2009;47(4):327–335.
- Ruha AM, Curry SC, Albrecht C, et al. Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune fab antivenom. Toxicon. 2011;57(1):53–59.
- Lavonas EJ, Ruha AM, Banner W, Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011;11:2.
- Bush S, Ruha AM, Seifert S, et al. Comparison of F(ab’)2 versus fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. Clin Toxicol. 2015;53(1):37–45.
- Mascarenas DN, Fullerton L, Smolinske SC, et al. Comparison of F(ab')2 and Fab antivenoms in rattlesnake envenomation: First year's post-marketing experience with F(ab')2 in New Mexico. Toxicon. 2020;186:42–45.
- Ruha AM, Padilla-Jones A, Canning J, et al. Early experience with crotalidae immune F(ab’)2 antivenom to treat Arizona rattlesnake envenomations. J Med Toxicol. 2021;18:38–42.
- Farrugia LA, Rhyee SH, Campleman SH, Toxicology Investigators Consortium (ToxIC) Study Group, et al. The toxicology investigators consortium case registry-the 2017 Annual Report. J Med Toxicol. 2018;14(3):182–211.
- Bailey AM, Justice S, Davis GA, et al. Delayed hematologic toxicity following rattlesnake envenomation unresponsive to crotalidae polyvalent antivenom. Am J of Emerg Med. 2017;35:1038e1–1038e2.
- Moore EC, Porter LM, Ruha AM. Rattlesnake venom-induced recurrent coagulopathy in first trimester pregnant women - Two Cases. Toxicon. 2019;163:8–11.
- Kitchens C, Eskin T. Fatality in a case of envenomation by Crotalus adamanteus initially successfully treated with polyvalent ovine antivenom followed by recurrence of defibrinogenation syndrome. J Med Toxicol. 2008;4(3):180–183.